nanotech investing Longeveron Granted Small or Medium-sized Enterprise Status by the European Medicines Agency
nanotech investing Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
nanotech investing Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
nanotech investing Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome
nanotech investing Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome
nanotech investing Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
nanotech investing Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells
nanotech investing Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells
nanotech investing The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
nanotech investing Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
nanotech investing Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
